← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
The Wistar Institute Of Anatomy And Biology
$20,149,951
Total funding
25
Grants
Funding over time
peak $4.7M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
DOD$20,149,951 · 25
By mechanism
—$20,149,951 · 25
Investigators at The Wistar Institute Of Anatomy And Biology
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
CLINICAL DEVELOPMENT OF GAMITRINIB, A NOVEL MITOCHONDRIAL-TARGETED SMALL MOLECULE HSP90 INHIBITOR$1,873,798
· FY2013 · Department of Defense
OPTIMIZING ACTIVE IMMUNOTHERAPY OF MELANOMA THROUGH METABOLIC REPROGRAMMING OF MELANOMA ANTIGEN-SPECIFIC CD8+ T CELLS COMBINED WITH CHECKPOINT BLOCKADE$1,746,270
· FY2019 · Department of the Army
UNDERSTANDING THE IMMUNE BIOLOGY OF CHECKPOINT INHIBITORS TO DEVELOP NEW STRATEGIES FOR THERAPY$1,348,203
· FY2016 · Department of the Army
DETERMINE THE ROLE OF CANONICAL WNT SIGNALING IN OVARIAN TUMORIGENESIS$1,264,845
· FY2010 · Department of Defense
OVERCOMING PLATINUM RESISTANCE IN OVARIAN CANCER THROUGH BET INHIBITION$1,111,331
· FY2018 · Defense Health Agency
IMMUNOTHERAPEUTIC TARGETING OF SLC39A9 IN CDKN2A-LOW MELANOMA$1,101,574
· FY2025 · Defense Health Agency
EPIGENETIC REPROGRAMMING TO TARGET SENESCENT OVARIAN CANCER CELLS AND OVERCOME THERAPEUTIC RESISTANCE FEB 4, 2026, MOD 1 TRANSFERRED AWARD TO WISTAR INSTITUTE$954,000
· FY2025 · Defense Health Agency
A FIRST IN HUMAN, PHASE I CLINICAL TRIAL OF MITOCHONDRIAL-TARGETED HSP90 INHIBITOR, GAMITRINIB IN ADVANCED AND METASTATIC PROSTATE CANCER$905,449
· FY2018 · Department of the Army
SYNTHETIC LETHAL THERAPEUTIC APPROACHES FOR ARIDIA-MUTATED OVARIAN CANCER$818,566
· FY2016 · Department of the Army
METABOLIC APPROACHES FOR ARID1A-MUTATED OVARIAN CANCER$803,700
· FY2020 · Defense Health Agency
IMMUNOLOGICAL APPROACHES FOR ARID1A-MUTATED OVARIAN CANCER$803,700
· FY2019 · Department of the Army
CHARACTERIZATION OF NOVEL VACCINE TARGETING FOLLICLE-STIMULATING HORMONE RECEPTOR IN OVARIAN CANCER$781,699
· FY2019 · Department of the Army
MYELOID-DERIVED SUPPRESSOR CELLS IN CHECKPOINT PROTEIN INHIBITION FOR MELANOMA$727,540
· FY2016 · Department of the Army
MYELOID-DERIVED SUPPRESSOR CELLS IN CHECKPOINT PROTEIN INHIBITION FOR MELANOMA$727,275
· FY2016 · Department of the Army
REGULATION OF MYELOMA PROGRESSION BY PROTEIN CITRULLINATION$690,726
· FY2019 · Defense Health Agency
THE SNAIL-INDUCED SULFONATION PATHWAY IN BREAST CANCER METASTASIS$584,205
· FY2011 · Department of the Army
CONTROL OF COLON CANCER PROGRESSION BY THE COLON MICROBIOME$543,815
· FY2014 · Department of Defense
TARGETING ACRAL MELANOMA BY INDUCING TERT DEGRADATION (ME190011). NEW AWARD.$535,800
· FY2020 · Defense Health Agency
A MACHINE LEARNING ALGORITHM TO ACCELERATE DEVELOPMENT OF IN VIVO DNA-VECTORED ANTIBODY COUNTERMEASURES FOR THE WARFIGHTER$500,000
· FY2020 · Department of the Navy
TWIST MAINTAINS STEMNESS IN LATENT BREAST CANCER METASTASES THROUGH A NOVEL NON-DNA-BINDING FUNCTION TARGETABLE WITH SMALL MOLECULES$473,823
· FY2017 · Department of the Army